Skip to content

Eyelid massager effectiveness in meibomian gland dysfunction

Investigating the efficacy of the Eyepeace eyelid massager in patients with meibomian gland dysfunction related evaporative dry eye

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN18423965
Enrollment
100
Registered
2017-02-21
Start date
2017-06-01
Completion date
Unknown
Last updated
2017-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Meibomian gland dysfunction Eye Diseases

Interventions

Participants are randomised by random number generation to one of two groups (the researcher who tests the patients will not know whether they belong to the study group or control group): 1. Participa

Sponsors

Cathedral Eye Clinic
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged 18 or over 2. Have otherwise healthy eyes 3. Are prepared not to wear contact lens for 3 months of the trial 4. Have a NITBUT <10s 5. OSDI score: greater than or equal to 12 6. Symptom frequency at least "some of the time" 7. Presence of cloudy fluid expressed from at least 1 of the central 8 glands on the lower/upper lid AND/OR presence of poor expressibility from at least 2-3 of the central 8 glands on the lower lid

Exclusion criteria

Exclusion criteria: 1. Conjunctivitis 2. Meibomian cysts 3. Styes 4. Damage to the cornea 5. Ocular injury 6. Cataract or laser refractive surgery in the past 6-months 7. Increased intraocular pressure (primary or secondary) 8. Any chronic disease of the eye

Design outcomes

Primary

MeasureTime frame
1. Tear film lipid layer thickness for right and left eyes, measured using images captured with Tearscope at 2 weeks, 1 month, 2 months and 3 months

Secondary

MeasureTime frame
Measured at baseline, 2 weeks, 1 month, 2 months and 3 months: 1. Tear film quality, measured as non-invasive tear break up time using a slit-lamp-mounted TearScope on each eye in random order 2. Meibomian gland function, based upon meibum quality and expressibility using a slit-lamp following firm digital pressure to the eyelid margins 3. Ocular redness/hyperaemia, measured using images captured non-invasively using a digital slit-lamp photography of the limbal and temporal conjunctiva for both eyes 4. Tear osmolarity for right and left eyes, measured using TearLab 5. Corneal sensitivity for right and left eyes, measured using handheld esthesiometer (Cochet-Bonnet) 6. Corneal staining for right and left eyes, assessed via instillation of lissamine green and fluorescein sodium and using the Oxford corneal grading score 7. Dry eye symptoms for right and left eyes, measured using the Ocular Surface Disease Index 8. Visual satisfaction, measured with Quality of Vision (QOV) questionnaire scores 9. Longitudinal progress of the patient’s dry eye symptoms and adherence to dry eye treatment, measured with the D-III questionnaire

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026